IGC Pharma Makes Progress in Alzheimer's Trial Despite Financial Challenges

IGC Pharma has reached 65% enrollment in its Phase 2 CALMA clinical trial for Alzheimer's treatment. The company operates in the biotechnology sector, focusing on cannabinoid-based therapies. However, it faces financial challenges, with negative margins and a low Altman Z-Score indicating distress. The company's valuation metrics reflect its speculative nature, with a high P/S ratio and P/B ratio. IGC Pharma also faces risks, including financial health grades indicating distress and sector-specific risks in the biotechnology industry.